Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
Charlotte, NC
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1218.75.096 Boehringer Ingelheim Investigational Site
mi
from
Akron, OH
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1218.75.096 Boehringer Ingelheim Investigational Site
mi
from
Akron, OH
Click here to add this to my saved trials
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1245.25.10156 Boehringer Ingelheim Investigational Site
mi
from
Kettering, OH
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1245.25.10156 Boehringer Ingelheim Investigational Site
mi
from
Kettering, OH
Click here to add this to my saved trials
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
205.452.01323 Boehringer Ingelheim Investigational Site
mi
from
Erie, PA
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
205.452.01323 Boehringer Ingelheim Investigational Site
mi
from
Erie, PA
Click here to add this to my saved trials
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
Pittsburgh, PA
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1160.129.32082 Boehringer Ingelheim Investigational Site
mi
from
Knoxville, TN
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1160.129.32082 Boehringer Ingelheim Investigational Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1218.75.030 Boehringer Ingelheim Investigational Site
mi
from
Memphis, TN
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1218.75.030 Boehringer Ingelheim Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
Dallas, TX
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1160.186.11187 Boehringer Ingelheim Investigational Site
mi
from
Orem, UT
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1160.186.11187 Boehringer Ingelheim Investigational Site
mi
from
Orem, UT
Click here to add this to my saved trials
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1160.129.32640 Boehringer Ingelheim Investigational Site
mi
from
Port Orchard, WA
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1160.129.32640 Boehringer Ingelheim Investigational Site
mi
from
Port Orchard, WA
Click here to add this to my saved trials
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1237.4.0203 Boehringer Ingelheim Investigational Site
mi
from
Winnipeg,
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1237.4.0203 Boehringer Ingelheim Investigational Site
mi
from
Winnipeg,
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Los Angeles Clinical Site 110
mi
from
Los Angeles, CA
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Los Angeles Clinical Site 110
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Mission Hills Clinical Site
mi
from
Mission Hills, CA
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Mission Hills Clinical Site
mi
from
Mission Hills, CA
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Newport Beach Clinical Site
mi
from
Newport Beach, CA
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Newport Beach Clinical Site
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Pasadena Clinical Site
mi
from
Pasadena, CA
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Pasadena Clinical Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Petaluma Clinical Site - Site 05
mi
from
Petaluma, CA
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Petaluma Clinical Site - Site 05
mi
from
Petaluma, CA
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Morrow Clinical Site
mi
from
Morrow, GA
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Morrow Clinical Site
mi
from
Morrow, GA
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Roswell Clinical Site
mi
from
Roswell, GA
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Roswell Clinical Site
mi
from
Roswell, GA
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
New York Clinical Site
mi
from
New York, NY
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
New York Clinical Site
mi
from
New York, NY
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
High Point Clinical Site - Site 06
mi
from
High Point, NC
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
High Point Clinical Site - Site 06
mi
from
High Point, NC
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Cranberry Township Clinical Site
mi
from
Cranberry Township, PA
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Cranberry Township Clinical Site
mi
from
Cranberry Township, PA
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Philadelphia Clinical Site 120
mi
from
Philadelphia, PA
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Philadelphia Clinical Site 120
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Austin Clinical Site
mi
from
Austin, TX
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Austin Clinical Site
mi
from
Austin, TX
Click here to add this to my saved trials
Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study
Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study
Status: Enrolling
Updated:  1/27/2016
Emory University
mi
from
Atlanta, GA
Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study
Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study
Status: Enrolling
Updated: 1/27/2016
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated:  1/27/2016
Clinical Research Facility
mi
from
Aurora, CO
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated: 1/27/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated:  1/27/2016
Clinical Research Facility
mi
from
Boston, MA
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated: 1/27/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated:  1/27/2016
Clinical Research Facility
mi
from
Rochester, MN
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated: 1/27/2016
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated:  1/27/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated: 1/27/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated:  1/27/2016
mi
from
Newtown,
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated: 1/27/2016
mi
from
Newtown,
Click here to add this to my saved trials
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  1/27/2016
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 1/27/2016
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
Click here to add this to my saved trials
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  1/27/2016
North Bay Eye Associates
mi
from
Petaluma, CA
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 1/27/2016
North Bay Eye Associates
mi
from
Petaluma, CA
Click here to add this to my saved trials
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  1/27/2016
Eye Care Centers Management/Clayton Eye Center
mi
from
Morrow, GA
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 1/27/2016
Eye Care Centers Management/Clayton Eye Center
mi
from
Morrow, GA
Click here to add this to my saved trials
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  1/27/2016
Taustin Eye Center
mi
from
Louisville, KY
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 1/27/2016
Taustin Eye Center
mi
from
Louisville, KY
Click here to add this to my saved trials
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  1/27/2016
East Tallin Central Hospital
mi
from
Tallin,
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 1/27/2016
East Tallin Central Hospital
mi
from
Tallin,
Click here to add this to my saved trials
Effect of EGCG on the Body's Response to Insulin
An Exploratory Study to Evaluate the Ability of Epigallocatechin Gallate to Simultaneously Improve Metabolic and Cardiovascular Actions of Insulin in Healthy and Obese Subjects
Status: Enrolling
Updated:  1/28/2016
University of Maryland
mi
from
Baltimore, MD
Effect of EGCG on the Body's Response to Insulin
An Exploratory Study to Evaluate the Ability of Epigallocatechin Gallate to Simultaneously Improve Metabolic and Cardiovascular Actions of Insulin in Healthy and Obese Subjects
Status: Enrolling
Updated: 1/28/2016
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension
Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension
Status: Enrolling
Updated:  1/29/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension
Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension
Status: Enrolling
Updated: 1/29/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension
Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension
Status: Enrolling
Updated:  1/29/2016
Ohio State University/Nationwide Children's Hospital
mi
from
Columbus, OH
Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension
Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension
Status: Enrolling
Updated: 1/29/2016
Ohio State University/Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Genetic and Environmental Characteristics of Primary Pulmonary Hypertension
Genetic and Environmental Pathogenesis of PPH
Status: Enrolling
Updated:  2/1/2016
Vanderbilt University Medical Center
mi
from
Nashville, TN
Genetic and Environmental Characteristics of Primary Pulmonary Hypertension
Genetic and Environmental Pathogenesis of PPH
Status: Enrolling
Updated: 2/1/2016
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Effects of Xoçai Antioxidant Supplements on Atherosclerosis Risk Factors
Effects of Xoçai Antioxidant Supplements on Atherosclerosis Risk Factors
Status: Enrolling
Updated:  2/4/2016
Cardiovascular Genetics, University of Utah
mi
from
Salt Lake City, UT
Effects of Xoçai Antioxidant Supplements on Atherosclerosis Risk Factors
Effects of Xoçai Antioxidant Supplements on Atherosclerosis Risk Factors
Status: Enrolling
Updated: 2/4/2016
Cardiovascular Genetics, University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated:  2/5/2016
Banner University Medical Center Phoenix Advanced Lung Disease
mi
from
Phoenix, AZ
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated: 2/5/2016
Banner University Medical Center Phoenix Advanced Lung Disease
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated:  2/5/2016
University of California, Los Angeles - Pulmonary Division
mi
from
Los Angeles, CA
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated: 2/5/2016
University of California, Los Angeles - Pulmonary Division
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated:  2/5/2016
University of California - Davis Medical Group
mi
from
Sacramento, CA
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated: 2/5/2016
University of California - Davis Medical Group
mi
from
Sacramento, CA
Click here to add this to my saved trials
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated:  2/5/2016
Emory University Hospital
mi
from
Atlanta, GA
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated: 2/5/2016
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated:  2/5/2016
Johns Hopkins University
mi
from
Baltiomore, MD
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated: 2/5/2016
Johns Hopkins University
mi
from
Baltiomore, MD
Click here to add this to my saved trials
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated:  2/5/2016
Oregon Health and Science University
mi
from
Portland, OR
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated: 2/5/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated:  2/5/2016
CLC Pulmonary Hypertension Clinic Division of Pulmonary, Allergy and Critical Care Medicine UPMC
mi
from
Pittsburgh, PA
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status: Enrolling
Updated: 2/5/2016
CLC Pulmonary Hypertension Clinic Division of Pulmonary, Allergy and Critical Care Medicine UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System
A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System
Status: Enrolling
Updated:  2/8/2016
Oregon Health and Science University
mi
from
Portland, OR
A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System
A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System
Status: Enrolling
Updated: 2/8/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis Investigator Site
mi
from
Birmingham, AL
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials